Nebulized Bacteriophage in a Patient With Refractory <i>Mycobacterium abscessus</i> Lung Disease-Reference-Cited by-同舟云学术

Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease

Published:2022-04-12 Issue:7 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Dedrick Rebekah M¹,Freeman Krista G¹,Nguyen Jan A²,Bahadirli-Talbott Asli²,Cardin Mitchell E²,Cristinziano Madison¹,Smith Bailey E¹,Jeong Soowan²,Ignatius Elisa H³⁴,Lin Cheng Ting⁵,Cohen Keira A²,Hatfull Graham F¹^ORCID

Affiliation:

1. Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania , USA

2. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

3. Division of Clinical Pharmacology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

4. Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

5. Department of Radiology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

Abstract

Abstract An elderly man with refractory Mycobacterium abscessus lung disease previously developed anti-phage neutralizing antibodies while receiving intravenous phage therapy. Subsequent phage nebulization resulted in transient weight gain, decreased C-reactive protein, and reduced Mycobacterium burden. Weak sputum neutralization may have limited the outcomes, but phage resistance was not a contributing factor.

Funder

Cystic Fibrosis Foundation

National Institutes of Health

Howard Hughes Medical Institute

Fowler Fund for Phage Research

National Heart, Lung, and Blood Institute

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac194/43370781/ofac194.pdf